IBA Molecular finalizes purchase of Mallinckrodt unit

By AuntMinnieEurope.com staff writers

January 30, 2017 -- Radiopharmacy vendor IBA Molecular has successfully completed its acquisition of Mallinckrodt's nuclear imaging business.

The companies reported that IBA Molecular would acquire the Mallinckrodt business in a deal first announced in August 2016. The new entity will encompass 21 manufacturing centers (including three SPECT sites, one molybdenum manufacturing facility, and 17 PET sites), as well as commercial operations across 60 countries.

It will also employ more than 1,500 people globally, supplying more than 6,000 public and private hospitals around the world with its systems.

Nuclear imaging will be the core of the enlarged business, and a new name and brand is currently being developed, due to be rolled out in the coming months. In the interim, the firms will continue to operate as IBA Molecular and Mallinckrodt Nuclear Imaging. Renaud Dehareng, the current CEO of IBA Molecular, is also the new CEO of the enlarged group.


Copyright © 2017 AuntMinnieEurope.com
 

To read this and get access to all of the exclusive content on AuntMinnieEurope.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnieEurope.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: